GRAIL Past Earnings Performance
Past criteria checks 0/6
GRAIL's earnings have been declining at an average annual rate of -56.3%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 80.2% per year.
Key information
-56.3%
Earnings growth rate
n/a
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | 80.2% |
Return on equity | -39.9% |
Net Margin | -1,488.2% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How GRAIL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 100 | -1,491 | 357 | 354 |
31 Dec 23 | 93 | -1,466 | 345 | 339 |
01 Jan 23 | 56 | -5,399 | 284 | 330 |
02 Jan 22 | 15 | -1,248 | 234 | 283 |
30 Jun 21 | 1 | -387 | 172 | 216 |
31 Mar 21 | 0 | -350 | 148 | 204 |
31 Dec 20 | 0 | -312 | 124 | 193 |
30 Sep 20 | 0 | -284 | 113 | 174 |
30 Jun 20 | 0 | -264 | 105 | 165 |
31 Mar 20 | 0 | -254 | 97 | 165 |
31 Dec 19 | 0 | -245 | 89 | 165 |
Quality Earnings: NL0 is currently unprofitable.
Growing Profit Margin: NL0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NL0 is unprofitable, and losses have increased over the past 5 years at a rate of 56.3% per year.
Accelerating Growth: Unable to compare NL0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NL0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.9%).
Return on Equity
High ROE: NL0 has a negative Return on Equity (-39.87%), as it is currently unprofitable.